Beta Bionics, Inc.
BBNX
$10.62
-$0.34-3.10%
NASDAQ
| 12/31/2024 | |||||
|---|---|---|---|---|---|
| Revenue | 22.36% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | 22.36% | ||||
| Cost of Revenue | 12.32% | ||||
| Gross Profit | 31.13% | ||||
| SG&A Expenses | 5.17% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 20.93% | ||||
| Operating Income | -18.77% | ||||
| Income Before Tax | -85.99% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -85.99% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -85.99% | ||||
| EBIT | -18.77% | ||||
| EBITDA | -20.00% | ||||
| EPS Basic | -74.79% | ||||
| Normalized Basic EPS | -74.79% | ||||
| EPS Diluted | -74.79% | ||||
| Normalized Diluted EPS | -74.79% | ||||
| Average Basic Shares Outstanding | 6.41% | ||||
| Average Diluted Shares Outstanding | 6.41% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||